601A anti-VEGF Ab is under clinical development by Sunshine Guojian Pharmaceutical Shanghai and currently in Phase III for Branch Retinal Vein Occlusion. According to GlobalData, Phase III drugs for ...

This project involves using Generative Adversarial Networks (GANs) to generate synthetic images and labels for Branch Retinal Vein Occlusion (BRVO), a vision-threatening retinal vascular condition. By ...

Background/aim: In patients with acute central retinal vein occlusion (CRVO), dynamic angiography may reveal the presence of pulsatile flow (termed here pulsatile venular outflow, PVO) within first ...

The dilemma still holds regarding treatment of the very ischemic central retinal vein occlusion subgroup with ME with profound visual loss. Combination therapy of anti-VEGF agents and a steroid ...

Faricimab is under development for the treatment of non-proliferative diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, diabetic retinopathy, ...

We present two cases of acute CSC that developed after intravitreal steroid injections. One was a case of diabetic macular oedema; another was a case of branch retinal vein occlusion-related macular ...

Fifty‐four year‐old male with no PMH presented with sudden right vision loss immediately after nasal septoplasty. Ophthalmology examination confirmed right CRAO and multiple left branch retinal artery ...

We propose an FFA-assisted multi-branch segmentation framework, named M3B-Net ... age-related macular degeneration, and retinal vein occlusion. Early detection can lead to timely interventions and ...